Biosurfactants Market Outlook 2026–2035: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines biosurfactants, meaning fermentation-made rhamnolipids, sophorolipids and mannosylerythritol lipids used in cleaning products, personal care and related uses in place of surfactants made from fossil oil or tropical oils. It tests how fast industrial scale plants move biosurfactants from a few thousand tonnes a year into mainstream cleaners, and which participants capture value among producers, chemical companies and consumer goods brands.

Scale is the first change. Combined production of rhamnolipids and sophorolipids was only a few thousand tonnes a year in 2023. Evonik then inaugurated its plant at Slovenská Ľupča, Slovakia on 29 May 2024, a facility of triple-digit million euros that the company describes as the first in the world to make industrial scale quantities of rhamnolipids, with capacity reported at double-digit kilotonnes a year. The conclusion is that a single plant lifts supply by an order of magnitude, and demand now has to fill it.

Smaller producers are scaling in step. Holiferm opened a sophorolipid plant at Wallasey, United Kingdom in February 2023 at a cost of GBP 8 million, with capacity of 1,600 tonnes a year, most of it taken by Sasol, and raised USD 23 million to scale toward 15,000 tonnes a year. Locus supplies sophorolipids to Dow for home and personal care and has tripled its capacity. The conclusion is that supply agreements with large chemical companies give small producers the volume to build plants.

Brands are testing and launching. Unilever piloted a rhamnolipid dish soap with Evonik, and AmphiStar launched a multi-surface cleaner for Ecover made with 97% food-waste-derived material in 2023. The conclusion is that cleaning is the first mass market for biosurfactants, and the pace of launches will decide how quickly new plants fill.

The brief treats biosurfactants as an accelerating signal with a nine year horizon to 2035. It identifies which products, regions and producers scale first and what each means for producers, chemical companies and consumer goods brands. It is a focused 104-page decision brief that presents an indicative trajectory rather than a segmented market model.

Biosurfactants are surface-active molecules made by fermentation of sugars or oils by yeast or bacteria, and they replace surfactants made from fossil oil or tropical oils in cleaners and personal care.

Rhamnolipids are made by bacteria and sophorolipids by yeast. Mannosylerythritol lipids are a third type that is nearing commercial launch.

Performance depends on cleaning power, foaming, mildness and biodegradability against cost. Evonik describes rhamnolipids as high performing, non-toxic and biodegradable.

Uses are dish and surface cleaners, laundry products, personal care, and smaller uses in agriculture, mining and coatings.

The limits are the cost gap to conventional surfactants, the capital cost of plants and approvals. The period turns on how fast new plants fill and costs fall.

The biosurfactants market, covering fermentation-made rhamnolipids, sophorolipids and mannosylerythritol lipids sold for cleaning, personal care and related uses, and excluding sugar-based and oleochemical surfactants made by chemical routes, is valued at USD 0.1–0.2 billion in 2026 and is projected to reach USD 0.75–1.49 billion by 2035, at a CAGR of 25%.

The 2026 base rests on sophorolipid sales from established producers and the first sales from industrial scale rhamnolipid capacity. Growth then follows plant utilisation, new capacity and adoption in home care and personal care.

The forecast is sensitive to the cost gap to conventional surfactants, brand owner commitments and approvals. Regionally, Europe leads on production and demand, North America follows through Locus and Dow, and Asia-Pacific has established sophorolipid producers.

The base case assumes new plants fill by 2028 and biosurfactants reach mainstream home care by 2030. An accelerated case assumes quick brand adoption and falling costs, bringing the inflection to 2028 and lifting the 2035 value to the top of the range. A delayed case assumes slow sales and a persistent cost gap, holding growth at the bottom of the range.

Growth drivers

• Demand from home care brands.
• Industrial scale plants.
• Biodegradability and mildness.
• Pressure on palm based feedstocks.

Enablers

• Venture and public funding.
• Supply agreements with chemical companies.
• Distributors.
• University spin-outs.

Restraints and barriers

• Capital intensity of plants.
• Cost gap to conventional surfactants.
• Limited production volumes.
• Regulatory approvals.

The direction of biosurfactants is set by demand for biodegradable cleaners, brand owner sustainability targets, substitution of fossil and palm based surfactants, chemical regulation, and the cost gap and capital intensity of plants.

The key participants in biosurfactants include Evonik Industries AG, Holiferm Limited, Locus Performance Ingredients, Inc., Sasol Limited, Dow Inc., Unilever PLC, AmphiStar NV, AGAE Technologies, LLC, Croda International Plc, BASF SE, Kao Corporation, Givaudan SA, Allied Carbon Solutions Co., Ltd., Saraya Co., Ltd., Stepan Company, Clariant AG, Henkel AG & Co. KGaA, The Procter & Gamble Company, Werner & Mertz GmbH, Jeneil Biotech, Inc., Biesterfeld AG, Azelis Group NV, ICOS Capital, Clean Growth Fund, Innovate UK, University of Manchester, Ghent University, Wageningen University & Research, Technical University of Denmark, Fraunhofer-Gesellschaft, National Renewable Energy Laboratory, American Chemical Society, European Chemicals Agency, European Commission, U.S. Environmental Protection Agency, International Association for Soaps, Detergents and Maintenance Products, American Cleaning Institute and Bio-based Industries Consortium.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as plants scale.

Evonik leads on rhamnolipids, Holiferm and Locus lead on sophorolipids, and Sasol and Dow lead among chemical companies buying supply. Competitive intensity is low in rhamnolipids and moderate in sophorolipids.

Where value migrates.

In 2026 value sits with producers that have industrial scale plants and supply agreements, because few producers can deliver volume. By 2031 it moves toward producers near cost parity with conventional surfactants, because brand owners buy at scale only when the gap closes. By 2035 it settles in integrated platforms that combine biosurfactant production with formulation. Margins hold for producers with high utilisation and low feedstock cost and narrow for those with idle capacity.

The signals converge on a move from small volumes to industrial scale. The first industrial scale rhamnolipid plant opened in May 2024, sophorolipid capacity is expanding, and brands have launched cleaners, while the cost gap, the capital cost of plants and approvals limit the pace.

Structural limits show where progress could slow: the cost gap to conventional surfactants, limited production volumes, regulatory approvals and the capital cost of plants. The brief therefore tracks four indicators: plant utilisation, supply agreements, brand launches and cost per tonne.

Sophorolipids in home care first, then rhamnolipids at scale, then mannosylerythritol lipids and personal care are the expected order of adoption.